$5.62 Billion in Sales Expected for Thermo Fisher Scientific Inc. (TMO) This Quarter

Equities research analysts expect Thermo Fisher Scientific Inc. (NYSE:TMO) to report sales of $5.62 billion for the current quarter, Zacks reports. Seven analysts have made estimates for Thermo Fisher Scientific’s earnings. The lowest sales estimate is $5.54 billion and the highest is $5.67 billion. Thermo Fisher Scientific reported sales of $4.77 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 17.8%. The business is expected to issue its next earnings results on Wednesday, April 25th.

According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year sales of $5.62 billion for the current year, with estimates ranging from $23.47 billion to $23.67 billion. For the next fiscal year, analysts forecast that the company will report sales of $24.82 billion per share, with estimates ranging from $24.49 billion to $25.95 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter last year, the company posted $2.41 earnings per share. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year.

A number of research firms recently issued reports on TMO. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a report on Thursday, March 22nd. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Leerink Swann restated an “outperform” rating and set a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday, February 1st. They noted that the move was a valuation call. ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Finally, Barclays increased their target price on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Two investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $222.29.

In other news, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total value of $7,321,941.90. Following the completion of the transaction, the senior vice president now directly owns 60,471 shares in the company, valued at $13,285,478.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $204.60, for a total transaction of $511,500.00. The disclosure for this sale can be found here. Insiders have sold 88,827 shares of company stock valued at $19,012,672 in the last quarter. Company insiders own 0.49% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Chemical Bank lifted its position in Thermo Fisher Scientific by 17.4% during the fourth quarter. Chemical Bank now owns 14,485 shares of the medical research company’s stock valued at $2,751,000 after purchasing an additional 2,148 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Thermo Fisher Scientific by 16.4% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 12,330 shares of the medical research company’s stock valued at $2,341,000 after purchasing an additional 1,737 shares during the last quarter. D.B. Root & Company LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $213,000. KCM Investment Advisors LLC lifted its position in Thermo Fisher Scientific by 28.8% during the fourth quarter. KCM Investment Advisors LLC now owns 3,883 shares of the medical research company’s stock valued at $737,000 after purchasing an additional 869 shares during the last quarter. Finally, Xact Kapitalforvaltning AB lifted its position in Thermo Fisher Scientific by 6.8% during the fourth quarter. Xact Kapitalforvaltning AB now owns 85,954 shares of the medical research company’s stock valued at $16,321,000 after purchasing an additional 5,509 shares during the last quarter. Institutional investors own 87.67% of the company’s stock.

NYSE TMO traded up $0.54 during trading hours on Tuesday, reaching $206.46. 1,787,684 shares of the company were exchanged, compared to its average volume of 1,455,100. Thermo Fisher Scientific has a 1 year low of $151.74 and a 1 year high of $226.44. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.34. The company has a market capitalization of $82,952.33, a PE ratio of 21.76, a price-to-earnings-growth ratio of 1.51 and a beta of 1.15.

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.17%.

COPYRIGHT VIOLATION NOTICE: This article was published by WKRB News and is owned by of WKRB News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.wkrb13.com/2018/04/02/5-62-billion-in-sales-expected-for-thermo-fisher-scientific-inc-tmo-this-quarter.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply